Stresam (Etifoxine) is a nonbenzodiazepine anxiolytic drug with unique pharmacological action. It is used since 1979 in more than 40 countries around the world.
Stresam produces an anti-anxiety effect by positive allosteric modulation of GABA receptors. It is also suggested that anxiolytic effect of the drug may be mediated by stimulating the biosynthesis of endogenous neurosteroids with anxiolytic properties.
In recent studies on animals, Etifoxine is shown to possess neurotrophic properties and promote peripheral nerve regeneration. These results suggest that Stresam appears promising in the treatment of peripheral nerve injuries.
Unlike commonly used anxiety drugs such as benzodiazepine tranquilizers, Stresam does not impair cognitive functions and does not cause withdrawals after cessation.